WallStSmart
RNA

Atrium Therapeutics, Inc. Common Stock

NASDAQ: RNA · HEALTHCARE · BIOTECHNOLOGY

$12.99
+3.51% today

Updated 2026-04-29

Market cap
$201.54M
P/E ratio
P/S ratio
10.82x
EPS (TTM)
$-4.48
Dividend yield
52W range
$12 – $17
Volume
1.5M

Atrium Therapeutics, Inc. Common Stock (RNA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20112012201320182019202020212022202320242025
Revenue$11.27M$10.36M$13.09M$379000.00$2.32M$6.79M$9.33M$9.22M$9.56M$10.90M$18.62M
Revenue growth (YoY)-8.1%+26.4%-97.1%+511.9%+192.7%+37.4%-1.1%+3.6%+14.0%+70.9%
Cost of revenue$25.28M$22.75M$32.51M$8.44M$14.54M$37.60M$639000.00$1.39M$2.10M$2.78M$4.15M
Gross profit$-8.06M$2.32M$6.79M$9.33M$9.22M$7.46M$10.90M$18.62M
Gross margin0.0%0.0%0.0%-2125.9%100.0%100.0%100.0%100.0%78.0%100.0%100.0%
R&D$19.91M$18.98M$25.44M$8.44M$14.54M$37.60M$101.18M$150.40M$190.97M$303.59M$53.76M
SG&A$2.44M$5.11M$13.46M$26.20M$37.73M$54.19M$86.24M$41.68M
Operating income$-10.50M$-17.33M$-44.28M$-118.05M$-178.91M$-235.60M$-378.94M$-76.81M
Operating margin0.0%0.0%0.0%-2769.9%-747.4%-652.4%-1265.8%-1939.6%-2464.4%-3477.4%-412.6%
EBITDA$-10.12M$-17.00M$-43.90M$-117.41M$-177.53M$-233.50M$-376.16M$-76.49M
EBITDA margin0.0%0.0%0.0%-2668.9%-733.0%-646.9%-1259.0%-1924.6%-2442.4%-3452.0%-410.8%
EBIT$-10.50M$-17.35M$-44.28M$-118.05M$-178.91M$-235.60M$-378.94M$-76.81M
Interest expense$0.00$0.00$0.00$718000.00$7.39M$209000.00$639000.00$5.69M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-11.93M$-24.73M$-43.98M$-117.37M$-169.08M$-212.22M$-322.30M$-76.68M
Net income growth (YoY)-107.3%-77.8%-166.9%-44.1%-25.5%-51.9%+76.2%
Profit margin0.0%0.0%0.0%-3148.8%-1066.6%-648.0%-1258.5%-1833.0%-2219.9%-2957.7%-411.9%